Restructuring

A successful pilot of Hunting's eco-friendly recovery solution doubled production in a mature Texas field, signaling a major shift for the EOR market.

Spin Master's interactive T. rex wins Toy of the Year, while the industry raises over $1M for charity and honors new Hall of Fame legends at the 2026 TOTY Awards.

Dowinx is pushing user-driven design and certified tech in its gaming chairs. But do these promises hold up under the pressure of long-term use?

The veteran-founded coffee brand is on the clock after its stock price fell below $1.00, triggering a six-month window to brew a market turnaround.

A new report reveals a nearly 6% drop in US beer shipments for 2025, signaling a major shift as consumers turn to spirits, cannabis, and NA options.

Rising repair costs and market volatility are forcing homeowners to rethink their selling strategy, seeking certainty over a potential bidding war.

As the tax deadline nears, sophisticated digital scams from viral TikTok myths to 'pig butchering' schemes are surging. Learn the red flags and protect your finances.

Elanco's founding chairman and innovation head are leaving, marking a pivotal leadership shift as the animal health giant charts its post-spin-off future.

A new book reveals why physician marriages are surprisingly stable and what every dual-career couple can learn from their success in balancing love and life.

Byreal's 2026 roadmap, revealed at Solana Accelerate, promises AI-driven liquidity and 24/7 real-world asset trading, aiming to woo institutions.

On its 30th anniversary, Entertainment Earth launches awards celebrating the vital role of independent retailers in the evolving collectibles industry.

A new 'Wuthering Heights' film arrives, but its true story may be its surprising link to the global phenomenon of the telenovela. How did it happen?

A firm promising huge returns and easy market access is gaining attention, but a lack of transparency and a controversial business model raise serious questions.

Magna beat Q4 expectations and raised its dividend, but a $591M tech impairment and looming Ford recall costs paint a complex picture for the auto giant.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

With strong financials and a focus on tech, Allegion's CEO will outline the security giant's long-term strategy for a digitally connected world.

With top executives set for major conferences, investors eye Mastercard's playbook for commercial payments and Americas growth amid fierce competition.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

Despite Q4 headwinds, the auto supplier's massive EV wins and deep focus on China fuel an ambitious 2026 forecast for double-digit profitability.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.